From ASCO: Updates in HER2-positive breast cancers
PUBLISHED: JUNE 05, 2013
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
Debu Tripathy, MD, editor-in-chief of CURE, discusses preliminary studies on combining Herceptin (trastuzumab) with existing drugs to treat HER2-positive breast cancer. These highlighted studies were presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.